Prognostic and clinicopathological value of systemic inflammation response index (SIRI) in patients with breast cancer: a meta-analysis

Many studies have explored the value of the systemic inflammation response index (SIRI) in predicting the prognosis of patients with breast cancer (BC); however, their findings remain controversial. Consequently, we performed the present meta-analysis to accurately identify the role of SIRI in predicting BC prognosis. PubMed, Embase, Cochrane Library, and Web of Science databases were comprehensively searched between their inception and February 10, 2024. The significance of SIRI in predicting overall survival (OS) and disease-free survival (DFS) in BC patients was analyzed by calculating pooled hazard ratios (HRs) and corresponding 95% confidence intervals (CIs). Eight articles involving 2,997 patients with BC were enrolled in the present study. According to our combined analysis, a higher SIRI was markedly associated with dismal OS (HR = 2.43, 95%CI = 1.42–4.15, <i>p</i> &lt; 0.001) but not poor DFS (HR = 2.59, 95%CI = 0.81–8.24, <i>p</i> = 0.107) in patients with BC. Moreover, based on the pooled results, a high SIRI was significantly related to T3–T4 stage (OR = 1.73, 95%CI = 1.40–2.14, <i>p</i> &lt; 0.001), N1–N3 stage (OR = 1.61, 95%CI = 1.37–1.91, <i>p</i> &lt; 0.001), TNM stage III (OR = 1.63, 95%CI = 1.34–1.98, <i>p</i> &lt; 0.001), and poor differentiation (OR = 1.25, 95%CI = 1.02–1.52, <i>p</i> = 0.028). According to our results, a high SIRI significantly predicted poor OS in patients with BC. Furthermore, elevated SIRI was also remarkably related to increased tumor size and later BC tumor stage. The SIRI can serve as a novel prognostic biomarker for patients with BC. Based on our knowledge, this study is the first meta-analysis to explore value of SIRI in predicting BC prognosis.According to our results, a high SIRI significantly predicted the dismal OS in BC patients.SIRI can serve as the novel prognostic biomarker for BC patients. Based on our knowledge, this study is the first meta-analysis to explore value of SIRI in predicting BC prognosis. According to our results, a high SIRI significantly predicted the dismal OS in BC patients. SIRI can serve as the novel prognostic biomarker for BC patients.